三阴乳腺癌新辅助化疗前后CD44v6的表达及临床意义

EXPRESSION OF CD44v6 IN TRIPLE-NEGATIVE BREAST CANNER PATIENTS BEFORE AND AFTER RECEIVING NEOADJUVANT CHEMOTHERAPY AND ITS CLINICAL SIGNIFICANCE

目的探讨新辅助治疗前后三阴乳腺癌组织中CD44v6的表达及临床意义。方法选取唐山市人民医院在2015年1月—2018年8月收治的三阴乳腺癌患者82例。应用免疫组织化学SP法检测每位患者在新辅助化疗前后乳腺癌组织中CD44v6的表达水平。结果82例患者在新辅助化疗前有61(74.39%)例CD44v6表达呈阳性,在新辅助化疗后有34例(41.46%)呈阳性。在新辅助化疗前后CD44v6表达水平显著降低,差异有统计学意义(χ^(2)=18.239,P<0.05)。处于Ⅱa期新辅助化疗前CD44v6阳性率为66.67%,化疗后为27.78%(χ^(2)=5.641,P<0.05);处于Ⅲa期新辅助化疗前CD44v6阳性率为80.00%,化疗后为48.57%(χ^(2)=7.529,P<0.05);处于Ⅲb期新辅助化疗前CD44v6阳性率为72.41%,化疗后为41.38%(χ^(2)=5.695,P<0.05),CD44v6阳性率均显著下降,差异均有统计学意义。处于Ⅱa期患者CD44v6阳性率明显下降(下降了38.89%),其次为Ⅲa期(下降了31.43%),Ⅲb期(下降了31.03%)。CD44v6水平与NAC的疗效呈负相关(r=-0.462,P<0.05)。结论三阴乳腺癌在新辅助化疗后CD44v6表达水平降低,CD44v6可作为化疗靶点,同时CD44v6表达水平变化可为临床判断疗效及预后提供依据。

Objective The aim of this study was to investigate the correlation between CD44 v6 and the effect of neoadjuvant chemotherapy(NAC)in patients with triple-negative breast cancer(TNBC).Methods Immunohistochemistry(SP)was used to determine the expression of CD44 v6 of eighty-two TNBC patients who were from Tangshan People’s Hospital during Jan 2015 to august 2018 before and after NAC.Results CD44 V6 expression was positive in sixty one(74.39%)of the 82 patients before neoadjuvant chemotherapy,and positive in 34(41.46%)patients after neoadjuvant chemotherapy.CD44 V6 expression level was significantly decreased before and after neoadjuvant chemotherapy,the difference was statistically significant(χ^(2)=18.239,P<0.05).CD44 V6 positive rate was 66.67%before neoadjuvant chemotherapy and 27.78%after chemotherapy(χ^(2)=5.641,P<0.05).The positive rate of CD44 v6 was 80.00%before neoadjuvant chemotherapy and 48.57%after chemotherapy(χ^(2)=7.529,P<0.05).The positive rate of CD44 V6 was 72.41%before and 41.38%after stage B neoadjuvant chemotherapy(χ^(2)=5.695,P<0.05),the positive rate of CD44 v6 was significantly decreased,and the differences were statistically significant.There was a negative correlation between CD44 v6 levels and the effect of NAC(r=-0.462,P<0.05).Conclusion After NAC,the expression level of CD44 v6 was decreased,and CD44 v6 may be a potential target for NAC in the treatment of TNBC.At the same time,changes in the expression level of CD44 v6 could provide a basis for clinical judgment of efficacy and prognosis.